# Intravitreal versus subtenon triamcinolone acetonide for the treatment of diabetic cystoid macular oedema

Recruitment status No longer recruiting	<ul><li>Prospectively registered</li></ul>		
	☐ Protocol		
Overall study status	Statistical analysis plan		
Completed	[X] Results		
Condition category	Individual participant data		
	No longer recruiting  Overall study status  Completed		

## Plain English summary of protocol

Not provided at time of registration

## Contact information

## Type(s)

Scientific

#### Contact name

Dr Mauro Cellini

#### Contact details

Via Massarenti, 9 Bologna Italy 40100

# Additional identifiers

**Protocol serial number** N/A

# Study information

Scientific Title

**Study objectives** 

Macular oedema is the main cause of loss of visual acuity in diabetic patients. It may occur at any stage of the retinal disorder and is the most common cause of sight reductions in these subjects.

In the oedema, the haemato-retinal barrier is damaged by an alteration in the tight junction between the retinal capillary endothelial cells and the pigmented epithelial cells with the consequent leakage of water and electrolytes in the retinal tissue.

The use of corticosteroids for the treatment of retinal oedema is linked to their capacity to inhibit the initial arachidonic acid cascade, to determine a down-regulation of the cytokines and to attenuate the tearing of the haemato-retinal barrier.

#### Hypothesis:

To assess the efficacy of the intravitreal (IVT) injection of triamcinolone acetonide (TA) as compared to posterior subtenon (SBT) capsule injection for the treatment of cystoid diabetic macular oedema.

#### Ethics approval required

Old ethics approval format

#### Ethics approval(s)

Ethics approval received from the Institutional Ethics Committee of the S. Orsola-Malpighi Hospital on the 12th September 2006 (ref: OFC06-01).

#### Study design

An interventional randomised double-blind study

#### Primary study design

Interventional

## Study type(s)

Treatment

## Health condition(s) or problem(s) studied

Macular oedema

#### Interventions

For the IVT injection, the patient was placed supine and we performed a surface anaesthesia with topical 4% carbocaine followed by a preparation with 5% povidone iodine. A volume of 0.1 ml containing 4 mg preservative-free TA (Kenacort, Bristol-Myers Squibb, Sermoneta, Italy) was injected through the inferotemporal pars-plana (4.0 mm posterior to the limbus) using a 30-gauge needle.

For the SBT injection, the patient was placed supine and after topical 0.4% oxybuprocaine surface anaesthesia we administered 0.5 ml of a 40 mg/ml peribulbar inferotemporal subtenon injection of preservative-free TA (Kenacort, Bristol-Myers Squibb, Sermoneta, Italy) with a 27-gauge needle.

The follow-up was of 6 months for all treatment arms.

#### Intervention Type

Drug

#### Phase

**Not Specified** 

#### Drug/device/biological/vaccine name(s)

Triamcinolone acetonide

#### Primary outcome(s)

Visual acuity was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) chart, measured every month until the end of follow-up.

#### Key secondary outcome(s))

Macular thickness was measured by optical coherence tomography (OCT), measured every month until the end of follow-up.

#### Completion date

18/10/2004

# **Eligibility**

#### Key inclusion criteria

- 1. Patients aged between 61 and 74 years (mean 68.3), either sex
- 2. With type II diabetes mellitus
- 3. On insulin treatment
- 4. Presenting diffuse macular oedema without retinal-vitreous traction

#### Participant type(s)

**Patient** 

## Healthy volunteers allowed

No

## Age group

Senior

#### Sex

All

#### Key exclusion criteria

- 1. History of focal/grid laser photocoagulation in the macula
- 2. Record of uveitis episodes
- 3. Previous ocular surgery, glaucoma and ocular hypertension

#### Date of first enrolment

03/02/2004

#### Date of final enrolment

18/10/2004

## Locations

#### Countries of recruitment

Italy

Study participating centre Via Massarenti, 9 Bologna Italy 40100

# Sponsor information

#### Organisation

St Orsola Malpighi University Hospital Bologna (Italy)

#### **ROR**

https://ror.org/00t4vnv68

# Funder(s)

## Funder type

Hospital/treatment centre

#### **Funder Name**

St Orsola Malpighi University Hospital Bologna (Italy)

## **Results and Publications**

Individual participant data (IPD) sharing plan

## IPD sharing plan summary

Not provided at time of registration

#### **Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	Results	17/03/2008		Yes	No